'Mr Market' may have unrealistically expected better, as in early trade to 1010 hours, UMG was down 1.81 per cent to $4.34.Perhaps also it perceives that the recent rise in the share price has been a little too fast/too much.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
